GHRP-6 [Peptide]

What is GHRP-6?

GHRP-6 (Growth Hormone-Releasing Peptide-6), also designated SK&F 110679 and Hexapeptide-2, is a synthetic hexapeptide of the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 - the founding member of the growth hormone-releasing peptide (GHRP) family. It was developed by Cyril Y. Bowers, Frank A. Momany, and colleagues at Tulane University, first characterised as the foundational hexapeptide in the landmark 1984 Endocrinology publication by Bowers, Momany, Reynolds, and Hong (PMID: 1592884). GHRP-6 was discovered through systematic chemical modification of met-enkephalin amide analogues - the observation that specific enkephalin modifications produced potent and selective GH release from pituitary somatotroph cells led to a new pharmacological category distinct from growth hormone-releasing hormone (GHRH).

GHRP-6 is a synthetic agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a) - the receptor subsequently identified as the endogenous ghrelin receptor when ghrelin was discovered in 1999. As the first compound to establish the existence of the GHS-R1a pharmacological target, GHRP-6 laid the foundation for the entire field of GH secretagogue research and for the discovery of the ghrelin signalling system. It is mechanistically and structurally distinct from GHRH: it acts through a G-protein coupled receptor (GHS-R1a) that is separate from the GHRH receptor, signals through intracellular calcium mobilisation rather than cAMP/PKA, and synergises with GHRH to produce supraphysiological GH release in combined administration protocols.

GHRP-6 is distinguished from its successors in the GHRP class - GHRP-2, hexarelin, and ipamorelin - by its pronounced orexigenic (appetite-stimulating) effect, the strongest of any GHRP. This appetite stimulation, mediated through hypothalamic GHS-R1a and neuropeptide Y pathways in preclinical preparations, makes GHRP-6 a useful tool compound in appetite and energy homeostasis research but produces a confounding variable in GH axis studies where appetite stimulation is undesired. GHRP-6 is not approved by the Food and Drug Administration for human or veterinary use. It is not a dietary supplement and is not intended for human consumption or therapeutic self-administration. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties

How Does GHRP-6 Work?

GHRP-6's pharmacological activity is mediated entirely through GHS-R1a receptor agonism, which initiates a distinct intracellular signalling cascade from GHRH and produces GH release through complementary but mechanistically separate pathways.

GHS-R1a (Ghrelin Receptor) Activation and Calcium Mobilisation

GHRP-6 binds GHS-R1a - a seven-transmembrane Gαq-coupled GPCR - with high affinity in pituitary and hypothalamic cell preparations [Howard et al., 1996]. Unlike the GHRH receptor (which signals through Gαs/cAMP/PKA), GHS-R1a signals primarily through Gαq-mediated phospholipase C activation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3-mediated intracellular calcium release from the endoplasmic reticulum, alongside inhibition of potassium channels and calcium channel activation, drives GH granule exocytosis from somatotroph cells. This calcium-dependent, cAMP-independent mechanism is complementary to GHRH's cAMP-dependent pathway, providing the basis for the well-characterised GHRP-6 + GHRH synergy in GH pulse amplitude amplification.

GHRH Synergy and Somatostatin Pathway Interactions

GHRP-6 and GHRH act through parallel, non-competing GH release mechanisms that produce supraphysiological GH responses when combined. In addition, GHRP-6 has been demonstrated to suppress hypothalamic somatostatin release in preclinical preparations - antagonising the principal GH inhibitory signal and thereby amplifying GH pulse amplitude through both direct somatotroph stimulation and indirect somatostatin suppression [Bowers et al., 1984]. This dual action - direct somatotroph stimulation plus somatostatin attenuation - is proposed as the mechanistic basis for GHRP-6's potent GH-releasing activity relative to compounds acting through only one pathway.

Hypothalamic Appetite and NPY Pathway Activation

GHS-R1a is highly expressed in hypothalamic nuclei, including the arcuate nucleus (ARC), where its activation by both ghrelin and GHRP-6 stimulates neuropeptide Y (NPY)/AgRP neurons - the primary hypothalamic orexigenic circuit. In preclinical rodent preparations, intracerebroventricular GHRP-6 administration produced rapid and dose-dependent food intake increases, with appetite stimulation comparable to that produced by the endogenous ligand ghrelin [Wren et al., 2000]. This hypothalamic GHS-R1a/NPY pathway activation is the mechanistic basis for GHRP-6's pronounced orexigenic effect - the compound's most clinically and experimentally notable distinguishing feature relative to GHRP-2 and ipamorelin.

Cortisol and Prolactin Pathway Effects

At higher doses in clinical and preclinical preparations, GHRP-6 produces modest elevations in ACTH/cortisol and prolactin concentrations in addition to GH release. This broader hormonal footprint is distinct from more selective GHS-R1a agonists (ipamorelin), which produce GH release without significant cortisol or prolactin changes in preclinical pituitary preparations. The ACTH/cortisol effect is proposed to occur through GHS-R1a expression in the hypothalamus and pituitary corticotrophs, with the mechanism remaining incompletely characterised.

Key Research Findings

In preclinical and early clinical research contexts, GHRP-6 has been associated with the following observations:

• Selective GH release - founding observation: Dose-dependent GH release from pituitary somatotrophs in vitro and in vivo across multiple species, including humans; specificity for GH versus other pituitary hormones (LH, FSH, TSH, ACTH unaffected at standard doses was established in the founding 1984 publication [Bowers et al., 1984].
• GHS-R1a receptor cloning: GHRP-6 pharmacological activity was the basis for GHS-R1a receptor cloning by Howard et al. in 1996 - the receptor subsequently identified as the endogenous ghrelin receptor [Howard et al., 1996].
• Human IV pharmacodynamic study: GHRP-6 (0.25–1.0 μg/kg IV) in 17 healthy men produced mean peak serum GH concentrations of 17.8 to 63.0 μg/L in a dose-dependent manner; LH, FSH, TSH, and ACTH were unaffected at these doses [Bensing et al., 1989].
• Orexigenic activity: Intracerebroventricular GHRP-6 produced rapid, dose-dependent food intake increases in rodent models; mechanistic overlap with ghrelin/NPY pathway identified [Wren et al., 2000].
• GHRH synergy: Combined GHRP-6 + GHRH administration produced supraphysiological GH responses in preclinical and clinical model preparations, with GH peak amplitudes exceeding those from either compound alone.

All findings listed above are derived from preclinical in vitro and in vivo data and early-phase human pharmacology studies. GHRP-6 is not approved by the FDA for any indication. These observations do not constitute evidence of safety or efficacy for research-grade material in any human condition or organism.

What are the Potential Research Applications of GHRP-6?

In controlled laboratory environments, GHRP-6 has been investigated for the following research applications. These do not constitute claims of efficacy or safety for research-grade material.

GHS-R1a Pharmacology and Ghrelin Receptor Research GHRP-6 is the founding reference agonist for GHS-R1a pharmacological studies. It is employed in radioligand displacement assays, calcium mobilisation reporter systems, and β-arrestin recruitment assays to characterise GHS-R1a binding affinity, receptor activation kinetics, and biased signalling profiles relative to endogenous ghrelin and next-generation selective GHSs.

Comparative GHRP Class Pharmacology GHRP-6 is employed as the reference compound in comparative studies examining the pharmacological evolution of the GHRP family - from GHRP-6 (broad footprint, appetite stimulation, cortisol/prolactin effects) through GHRP-2 (higher potency, reduced appetite) to hexarelin and ipamorelin (progressively more selective for GH without appetite or cortisol effects). Research characterises how structural modifications at each GHRP position alter receptor selectivity and signalling profiles.

Appetite, Energy Homeostasis, and NPY Circuit Research GHRP-6's pronounced orexigenic activity through GHS-R1a/NPY pathway activation makes it a useful tool in preclinical models examining hypothalamic appetite circuit biology. Research employs GHRP-6 as a pharmacological probe for arcuate nucleus NPY/AgRP neuron activation, food intake regulatory pathway studies, and comparative orexigenic mechanism analysis versus ghrelin.

GH Pulsatility and GHRH Synergy Research. In isolated pituitary preparations and rodent in vivo models, GHRP-6 is employed to characterise GH secretagogue-GHRH synergy mechanisms, including the calcium/cAMP cross-talk between GHS-R1a and GHRHR signalling cascades and the relationship between somatostatin suppression and GH pulse amplitude amplification.

Growth Hormone Axis and IGF-1 Pathway Studies. As a potent pituitary GH secretagogue, GHRP-6 is employed in preclinical models examining downstream GH axis activation, hepatic IGF-1 production, and the relationship between GHS-R1a agonism and somatic growth markers under various experimental conditions.

What are the Potential Side Effects of GHRP-6?

The following observations are from early-phase human pharmacology studies and preclinical data.

• Pronounced orexigenic effect - significantly stronger appetite stimulation than GHRP-2, hexarelin, or ipamorelin; observed in both rodent preclinical models and human subjects; mediated through GHS-R1a/NPY hypothalamic pathways
• Modest ACTH and cortisol elevations at higher doses observed in human pharmacology studies and preclinical preparations; dose-dependent; distinguishes GHRP-6 from more selective GHSs such as ipamorelin
• Transient prolactin elevations at higher doses in some human and preclinical preparations; mechanism not fully characterised
• Water retention consistent with GH axis activation is reported in human pharmacology studies
• Oral bioavailability <1% due to rapid GI peptidase degradation; intravenous or subcutaneous routes required for research pharmacodynamic activity
• No human safety or tolerability data have been established for research-grade GHRP-6 outside approved clinical study protocols. Observations above are from pharmacological studies and should not be extrapolated to research-grade material in unapproved use contexts.

Risk & Handling

Handling Precautions

GHRP-6 should only be handled by trained laboratory personnel. Appropriate PPE is required: nitrile gloves, a laboratory coat, and eye protection at a minimum. When working with lyophilized powder, use within a laminar flow cabinet. Avoid aerosol generation during reconstitution. The compound contains two D-amino acid residues (D-Trp, D-Phe) that confer resistance to aminopeptidase degradation; standard peptide handling precautions apply.

Exposure Risks

Risk Tier: MODERATE

GHRP-6 is a potent GHS-R1a agonist with well-characterised pharmacological activity at GH secretagogue, appetite stimulation, and cortisol pathways. Accidental systemic exposure at research concentrations may produce GH release, appetite stimulation, and modest cortisol elevation consistent with GHS-R1a pharmacology. The compound's approximately 2.5-hour half-life means effects from accidental exposure would be transient. No human safety data has been established for research-grade GHRP-6 outside pharmacological study protocols.

Storage

• Lyophilized form: Store at −20°C in original sealed, light-protected container with desiccant
• Reconstituted form: Store at 4°C; use within 48–72 hours of reconstitution
• Do not subject to repeated freeze-thaw cycles
• The two tryptophan residues (Trp and D-Trp) are sensitive to oxidative and photodegradation; they protect from light throughout storage and handling

Frequently Asked Questions

Q: What is GHRP-6, and what is it investigated for in research? A: GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is the founding member of the GHRP family, developed by Bowers et al. in 1984. It is a potent GHS-R1a (ghrelin receptor) agonist investigated in preclinical research contexts for growth hormone secretagogue pharmacology, ghrelin receptor pathway characterisation, hypothalamic appetite circuit research, and GHRH synergy studies. It is not approved by the FDA and is intended strictly for laboratory research purposes.

Q: How does GHRP-6 differ from GHRH? A: GHRH activates the GHRH receptor (Gαs-coupled; cAMP/PKA pathway) on somatotroph cells, producing GH release through protein kinase A-mediated exocytosis. GHRP-6 activates GHS-R1a (Gαq-coupled; IP3/calcium pathway) - a completely different receptor with a different intracellular signal. When both are administered together, their complementary signalling cascades converge on GH exocytosis, producing supraphysiological GH release exceeding either compound alone. GHRP-6 additionally suppresses somatostatin release, amplifying GH pulse amplitude through a second mechanism unavailable to GHRH alone.

Q: Why does GHRP-6 stimulate appetite more than other GHRPs? A: All GHRPs activate GHS-R1a, but GHRP-6's specific pharmacological profile - including its binding geometry at GHS-R1a in hypothalamic arcuate nucleus neurons - produces the most pronounced NPY/AgRP circuit activation and downstream orexigenic response of any GHRP in preclinical models. Subsequent GHRPs (GHRP-2, hexarelin) retain GH-releasing potency but produce less appetite stimulation. Ipamorelin - the most selective GHS - produces GH release without significant appetite, cortisol, or prolactin effects. These selectivity differences reflect structural modifications at specific GHRP sequence positions and are a primary research tool for mapping GHS-R1a structure-activity relationships.

Q: What was the historical significance of GHRP-6? A: GHRP-6 is significant on two levels. First, it was the first synthetic compound to demonstrate that the pituitary contains a GH-releasing receptor distinct from the GHRH receptor - a pharmacological target whose existence was unknown until Bowers et al.'s 1984 work. Second, its receptor became the basis for GHS-R1a cloning in 1996 (Howard et al., Science), which in turn enabled the 1999 discovery of ghrelin - the endogenous GHS-R1a ligand that revolutionised understanding of appetite and GH regulation. Without GHRP-6, neither the ghrelin receptor nor ghrelin itself would have been discovered when they were.

Q: What is the WADA status of GHRP-6? A: GHRP-6 is explicitly prohibited at all times under S2.2.4 (Growth Hormone Releasing Factors) of the 2026 WADA Prohibited List, listed by name among GH-releasing peptides including GHRP-1 through GHRP-6. Verify current status at GlobalDRO.com. Researchers in sport-adjacent contexts must verify their current status at GlobalDRO.com.

Q: How should GHRP-6 be stored? A: Lyophilized GHRP-6 should be stored at −20°C in a sealed, light-protected container with desiccant. The two tryptophan residues (Trp at position 4 and D-Trp at position 2) are sensitive to oxidative and photodegradative reactions - protected from light throughout storage and handling. Once reconstituted, store at 4°C and use within 48–72 hours. Avoid repeated freeze-thaw cycles. Visit RCD Bio to explore our full research compound catalog.